tetano
Editor, Senior Moderator
Viral Immunol. 2015 Oct 8. [Epub ahead of print]
[h=1]A New Adjuvant Combined with Inactivated Influenza Enhances Specific CD8 T Cell Response in Mice and Decreases Symptoms in Swine Upon Challenge.[/h] Bouguyon E[SUP]1[/SUP], Goncalves E[SUP]2[/SUP], Shevtsov A[SUP]3[/SUP], Maisonnasse P[SUP]1[/SUP], Remyga S[SUP]3[/SUP], Goryushev O[SUP]3[/SUP], Deville S[SUP]2[/SUP], Bertho N[SUP]1[/SUP], Ben Arous J[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination is the most effective way to control swine influenza virus (SIV) in the field. Classical vaccines are based on inactivated antigens formulated with an oil emulsion or a polymeric adjuvant. Standard adjuvants enhance the humoral response and orient the immune response toward a Th2 response. An important issue is that current vaccines do not protect against new strains. One approach to improve cross-protection is to enhance Th1 and cytotoxic responses. The development of adjuvants orienting the immune response of inactivated vaccines toward Th1/Cytotoxic responses would be highly beneficial. This study shows that the water in oil in water emulsion adjuvant Montanide? ISA 201 VG allows the induction of anti-influenza CD8 T cell in mice and induces homologous protection against an H1N1 challenge in swine. Such adjuvants that induce both humoral and cell-mediated immunity could improve the protection conferred by SIV vaccines in the field.
PMID: 26447972 [PubMed - as supplied by publisher]
[h=1]A New Adjuvant Combined with Inactivated Influenza Enhances Specific CD8 T Cell Response in Mice and Decreases Symptoms in Swine Upon Challenge.[/h] Bouguyon E[SUP]1[/SUP], Goncalves E[SUP]2[/SUP], Shevtsov A[SUP]3[/SUP], Maisonnasse P[SUP]1[/SUP], Remyga S[SUP]3[/SUP], Goryushev O[SUP]3[/SUP], Deville S[SUP]2[/SUP], Bertho N[SUP]1[/SUP], Ben Arous J[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Vaccination is the most effective way to control swine influenza virus (SIV) in the field. Classical vaccines are based on inactivated antigens formulated with an oil emulsion or a polymeric adjuvant. Standard adjuvants enhance the humoral response and orient the immune response toward a Th2 response. An important issue is that current vaccines do not protect against new strains. One approach to improve cross-protection is to enhance Th1 and cytotoxic responses. The development of adjuvants orienting the immune response of inactivated vaccines toward Th1/Cytotoxic responses would be highly beneficial. This study shows that the water in oil in water emulsion adjuvant Montanide? ISA 201 VG allows the induction of anti-influenza CD8 T cell in mice and induces homologous protection against an H1N1 challenge in swine. Such adjuvants that induce both humoral and cell-mediated immunity could improve the protection conferred by SIV vaccines in the field.
PMID: 26447972 [PubMed - as supplied by publisher]